HC Wainwright Has Bearish Estimate for Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Investment analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for Genelux in a research note issued on Monday, March 31st. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.25) per share for the quarter, down from their previous estimate of ($0.16). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.76) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at $1.32 EPS.

Genelux Stock Performance

Shares of GNLX stock opened at $2.39 on Thursday. The firm has a market capitalization of $83.00 million, a price-to-earnings ratio of -2.52 and a beta of -1.41. Genelux has a one year low of $1.60 and a one year high of $5.89. The company has a 50 day moving average price of $4.00 and a 200 day moving average price of $3.10.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09).

Institutional Trading of Genelux

Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP boosted its holdings in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after acquiring an additional 52,958 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Genelux in the 4th quarter valued at about $41,000. LPL Financial LLC grew its holdings in shares of Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after purchasing an additional 39,516 shares during the period. Virtu Financial LLC acquired a new stake in Genelux during the 4th quarter worth approximately $25,000. Finally, LifeSteps Financial Inc. raised its holdings in Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after buying an additional 8,715 shares during the period. 37.33% of the stock is owned by hedge funds and other institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.